Search results
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
Zacks via Yahoo Finance· 1 year agoThis week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone...
AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs
Zacks via Yahoo Finance· 1 year agoAbbVie ABBV announced multiple clinical updates pertaining to clinical studies evaluating its...
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via AOL· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
Zacks via Yahoo Finance· 9 months agoIn its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up...
AbbVie (ABBV) Q4 2022 Earnings Call Transcript
Motley Fool· 1 year agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q4 2022 Earnings Call Feb 09, 2023, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 days agoAbbVie ABBV will report first-quarter 2024 results on Apr 26, before market open. In the last...
AbbVie Psoriatic Arthritis Drug Shows Long-term Effect On Skin, Joint Symptoms
Benzinga via Yahoo Finance· 2 years agoAbbVie Inc (NASDAQ: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials...
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
Zacks via Yahoo Finance· 1 year agoAbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022,...
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
Zacks via Yahoo Finance· 8 months agoAbbVie’s ABBV key blockbuster immunology medicine, Humira lost patent protection in the United...
This Unstoppable Growth Stock Is Nearing a Once-In-a-Decade Buying Opportunity
Motley Fool· 1 year agoEven the most intrepid growth stocks experience doldrums, and such periods can be a great time to...